11.06.2024 - Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, .
Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on trackPALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) $VTGN #mentalhealth Vistagen (Nasdaq: VTGN), a late clinical-stag.